News & Insights

Tarsus Pharmaceuticals announces its securities purchase agreement with certain qualified institutional buyers and accredited investors for a private investment in public equity (“PIPE”) financing. 

Tarsus Pharmaceuticals announces its definitive agreement to acquire Alkeus Pharmaceuticals, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease.

Contineum Therapeutics, a clinical-stage biopharmaceutical company, announces the pricing of an upsized underwritten public offering of 7,346,938 shares of its Class A common stock at a public offering price of $12.25 per share.